Gleevec receives US approval as first treatment to reduce risk of cancer returning in patients with gastrointestinal stromal tum

2009-01-14 アップロード · 78 視聴

Novartis announced today that Gleevec® (imatinib mesylate) tablets* has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).

Gleevec is now the only post-surgery treatment indicated to delay the return of this highly aggressive cancer, filling a major need for GIST patients. The filing received FDA priority review status in August of this year, with regulatory reviews currently underway in other regions, including the European Union and Switzerland.

To view Multimedia News Release, go to http://www.prnewswire.com/mnr/novartis/35423/

tag·Gleevec,FDA,approval,GIST,reduce,risk,relapse,patients,cancer,Multivu

非会員の場合は、名前/パスワードを入力してください。

書き込む
今日のアクセス
18
全体アクセス
134,636
チャンネル会員数
35

My Video

リスト形式で表示 碁盤形式で表示